BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 25880479)

  • 21. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
    Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients.
    Taflampas P; Dayal S; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2014 May; 40(5):515-520. PubMed ID: 24462284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients.
    Baratti D; Kusamura S; Iusco D; Bonomi S; Grassi A; Virzì S; Leo E; Deraco M
    Dis Colon Rectum; 2014 Jul; 57(7):858-68. PubMed ID: 24901687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Feasibility of radical cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendiceal origin.
    Järvinen P; Ristimäki A; Kantonen J; Lepistö A
    Scand J Surg; 2013; 102(3):145-51. PubMed ID: 23963027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies.
    Passot G; Bakrin N; Isaac S; Decullier E; Gilly FN; Glehen O; Cotte E
    Eur J Surg Oncol; 2014 Aug; 40(8):957-62. PubMed ID: 24209429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
    Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases.
    Chua TC; Quinn LE; Zhao J; Morris DL
    J Surg Oncol; 2013 Aug; 108(2):81-8. PubMed ID: 23737041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours.
    Ansari N; Chandrakumaran K; Dayal S; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2016 Jul; 42(7):1035-41. PubMed ID: 27132072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix.
    Sparks DS; Morris B; Xu W; Fulton J; Atkinson V; Meade B; Lutton N
    Int Surg; 2015 Jan; 100(1):21-8. PubMed ID: 25594636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution.
    Teo MC; Tan GH; Tham CK; Lim C; Soo KC
    Ann Surg Oncol; 2013 Sep; 20(9):2968-74. PubMed ID: 23504144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secondary cytoreductive surgery and peri-operative intraperitoneal chemotherapy for peritoneal recurrence of colorectal and appendiceal peritoneal carcinomatosis following prior primary cytoreduction.
    Klaver YL; Chua TC; Verwaal VJ; de Hingh IH; Morris DL
    J Surg Oncol; 2013 May; 107(6):585-90. PubMed ID: 23280508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms.
    Narasimhan V; Pham T; Warrier S; Craig Lynch A; Michael M; Tie J; Ramsay R; Heriot A
    ANZ J Surg; 2019 Sep; 89(9):1035-1040. PubMed ID: 30685879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry.
    Arjona-Sanchez A; Aziz O; Passot G; Salti G; Esquivel J; Van der Speeten K; Piso P; Nedelcut DS; Sommariva A; Yonemura Y; Turaga K; Selvasekar CR; Rodriguez-Ortiz L; Sanchez-Hidalgo JM; Casado-Adam A; Rufian-Peña S; Briceño J; Glehen O
    Eur J Surg Oncol; 2021 Jun; 47(6):1420-1426. PubMed ID: 33298341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years.
    Vaira M; Cioppa T; D'Amico S; de Marco G; D'Alessandro M; Fiorentini G; De Simone M
    In Vivo; 2010; 24(1):79-84. PubMed ID: 20133981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus.
    Liu Y; Ishibashi H; Hirano M; Takeshita K; Mizumoto A; Ichinose M; Nishino E; Kashu I; Yamamoto Y; Sugarbaker PH; Yonemura Y
    Ann Surg Oncol; 2015 Aug; 22(8):2799-805. PubMed ID: 25572681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advanced Pseudomyxoma Peritonei Requiring Gastrectomy to Achieve Complete Cytoreduction Results in Good Long-Term Oncologic Outcomes.
    Di Fabio F; Mehta A; Chandrakumaran K; Mohamed F; Cecil T; Moran B
    Ann Surg Oncol; 2016 Dec; 23(13):4316-4321. PubMed ID: 27380645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peritoneal Cancers and Hyperthermic Intraperitoneal Chemotherapy.
    Pletcher E; Gleeson E; Labow D
    Surg Clin North Am; 2020 Jun; 100(3):589-613. PubMed ID: 32402303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
    Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
    In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overall survival of pseudomyxoma peritonei and peritoneal mesothelioma patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be predicted by computed tomography quantified sarcopenia.
    Galan A; Rousset P; Mercier F; Képénékian V; Valette PJ; Glehen O; Passot G
    Eur J Surg Oncol; 2018 Nov; 44(11):1818-1823. PubMed ID: 30143249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.